Related Experiment Video
Updated: Jan 31, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Abstract:
Since 2011, several effective drugs for patients with metastatic melanoma, including the BRAF inhibitors, the MEK inhibitors and the immune checkpoint inhibitors, have been ap- proved. Ipilimumab, nivolumab and the combination have shown response rates of 10-20%, 20-40% and up to 60% and a median progression-free survival of 2, 7 and 12 months, respec- tively. The management of immune related toxicities is keypoint for adequate use of these agents.
Insights
Effective treatments for metastatic melanoma, such as BRAF, MEK, and immune checkpoint inhibitors, have emerged since 2011. Managing immune-related toxicities is crucial for optimal patient outcomes with these therapies.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Metastatic melanoma treatment has advanced significantly since 2011.
- Several targeted therapies and immunotherapies are now available.
Purpose of the Study:
- To review the efficacy and management of novel drugs for metastatic melanoma.
- To highlight the importance of managing treatment-related toxicities.
Main Methods:
- Review of approved drugs including BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors.
- Analysis of response rates and progression-free survival data for key agents like ipilimumab and nivolumab.
Main Results:
- Immune checkpoint inhibitors (ipilimumab, nivolumab) show response rates from 10-60% and median progression-free survival of 2-12 months.
- Combination therapy demonstrates the highest efficacy.
- Effective management of immune-related toxicities is essential.
Conclusions:
- Novel therapies have dramatically improved outcomes for metastatic melanoma patients.
- Careful toxicity management is paramount for successful treatment with these agents.
